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dermal nitroglycerine (NTG) patch as an adjuvant to combined general epidural anesthesia
(CGEA) in patients undergoing lower abdominal surgery.
Method: Forty patients (ASA I or II) were randomly allocated to two equal groups; control group
(group C) and nitroglycerine group (group NG). Nitroderm patch, 5 mg, was applied to patients in
group NG, 2 h before surgery. All patients received epidural bolus of 18 ml of 0.25% bupivacaine
with fentanyl 2 lg/ml followed by continuous infusion at the rate of 5 ml/h combined with general
anesthesia. Patients used patient controlled analgesia (PCA) device to receive bolus dose of 5 ml of
patient controlled epidural analgesia (PCEA) solution containing bupivacaine 0.125% and fentanyl
2 lg/ml after surgery. Perioperative mean arterial blood pressure (MAP) and heart rate (HR), time
to ﬁrst rescue analgesic, postoperative bupivacaine and fentanyl consumption, and VAS pain scores
were measured for 24 h postoperatively. Patient satisfaction score was also recorded.
Results: Postoperative MAP and HR increased signiﬁcantly to both baseline and the other group
at 2 h in group C and at 4 h in group NG (p< 0.05). The time to ﬁrst rescue analgesic was signif-
icantly longer in group NG (238.62 ± 54.3 min) than in group C (126.75 ± 35.1 min) (p< 0.05).
Pain scores were signiﬁcantly higher compared to the other group at 2 h in group C and at 4 h
in group NG (p< 0.05). Postoperative bupivacaine and fentanyl consumption were signiﬁcantlyAnesthesiologists. Production
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20 M.M. Elgoharylower in group NG (74.91 ± 26.34 mg and 121.83 ± 32.5 lg, respectively) than in group C
(118.68 ± 29.4 mg and 194.21 ± 45.31 lg, respectively). Patient satisfaction was signiﬁcantly better
in group NG than in group C (p< 0.05).
Conclusion: Pre-emptive application of 5 mg transdermal nitroglycerine patch as adjuvant to
CGEA provided signiﬁcant prolongation of the postoperative analgesia and reduction of the post-
operative bupivacaine and fentanyl consumption.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
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Nitric oxide (NO) or NO donors have been reported to con-
tribute to the analgesia produced by morphine through activa-
tion of cyclic guanosine monophosphate (cGMP). There is
evidence that endogenous NO is necessary to inhibit nocicep-
tive transmission [1–3].
Because of the multiple mechanisms involved in postopera-
tive pain, a multimodal analgesic regimen could be used to en-
hance analgesic efﬁcacy and reduce unwanted side effects [4].
Data from the literature suggest that in humans high dose
nitroglycerine (NTG) patches (NO donor), such as 30 mg dai-
ly, are hyperalgesic, whereas doses less than 6 mg/day are anal-
gesic under different circumstances [5,6]. Transdermal NTG
patches improved oral morphine and ketamine analgesia for
cancer pain management [7].
The use of NTG patches for intraoperative and postopera-
tive pain control has been studied [8,9].
Several researches stated that NTG patch application in
addition to neuroaxial S(+)-ketamine, neostigmine or sufenta-
nil [9,10,5], enhance postoperative analgesia and reduce the
need for other analgesic medication.
The present study was designed as a randomized double
blinded controlled study to evaluate the efﬁcacy of pre-emptive
usage of transdermal patch 5 mg as adjuvant to combined gen-
eral epidural anesthesia in patients undergoing lower abdomi-
nal surgery. Perioperative hemodynamics, postoperative local
anaesthetic and fentanyl requirements and postoperative anal-
gesia were studied.
2. Materials and methods
After obtaining Ethics and Research Committee approval
and informed written consent, 40 patients aged 20–60 years,
ASA physical status I or II, scheduled for lower abdominal
surgery under combined general/epidural anaesthesia
(CGEA) were studied. Exclusion criteria included cerebro-
vascular, neurological disorder, history of major back dis-
ease or known allergy to amide local anaesthetics. The
night before surgery all patients were instructed on the use
of patient controlled epidural analgesia (PCEA) device and
how to assess their pain using a 10-cm visual analogue score
(VAS), with 0 representing no pain at all and 10 represent-
ing the worst imaginable pain.
Patients were randomly allocated using computer-gener-
ated randomization to two equal groups (n= 20), control
group (group C) and nitroglycerine group (group NG). Two
hours before surgery, an assistant anaesthetist not involved
in data collection applied a transdermal nitroglycerine patch,
5 mg (Nitroderm TTS 5, Novartis Pharma, AG Basle, Swit-
zerland) at the patients’ chest wall and covered it with a sterile
gauze and tape in group NG or applied a sterile gauze of samesize and shape only in group C. All patients were premedicated
with i.v. 0.02 mg/kg midazolam in the holding room.
On arrival to the operating room (OR) standard monitors
were applied (Viralert 2000, North American Dra¨ger) and
heart rate (HR), mean arterial blood pressure (MAP) and oxy-
gen saturation were recorded.
Before induction of general anesthesia (GA), all patients re-
ceived ﬂuid preload consisting of 10 ml/kg i.v. lactated Ring-
er’s solution. Then, an epidural puncture was performed
under complete aseptic condition with a 18-gauge Tuohy nee-
dle inserted at the L2–3 or L3–4 interspace using loss of resis-
tance to saline technique. A 20-gauge catheter was inserted
cephalad 4–5 cm into the epidural space. After negative aspira-
tion of blood and cerebrospinal ﬂuid, the proper placement
was tested using 3 ml lidocaine 2% containing 1:200,000 epi-
nephrine then, the catheter was secured. An epidural loading
dose of 18 ml of bupivacaine 0.25% plus 2 lg/ml fentanyl
was administered to achieve a sensory level at T10. The effect
of somatosensory blockade was tested bilaterally at the midcla-
vicular line after 15–30 min by dull and sharp end of safety pin
and alcohol-soaked swab. The block was maintained with con-
tinuous infusion of 0.25% bupivacaine with fentanyl 2 lg/ml
at the rate of 5 ml/h, started 1 h after the loading dose until
the end of surgery.
After preoxygenation, general anaesthesia was induced in
all patients with intravenous fentanyl 2 lg/kg and propofol
2–3 mg/kg. Vecuronium 0.08 mg/kg was used to facilitate tra-
cheal intubation. General anaesthesia was maintained with iso-
ﬂurane (0.5–1 minimum alveolar concentration) in 100%
oxygen and vecuronium. All patients were mechanically venti-
lated to maintain end-tidal carbon dioxide between 35 and
40 mmHg. The anesthesiologist involved in data collection
was blinded to the group assignment.
Hypotension (deﬁned as a drop of MAP more than 20% of
preoperative value) was treated with a ﬂuid challenge of 300 ml
of lactated Ringer’s solution followed by boluses of 5 mg
ephedrine if necessary.
MAP and HR were recorded before epidural anaesthesia
(base line T0), before induction of general anaesthesia (T1),
immediately after induction (T2) and every 10 min intraopera-
tively till the end of surgery [mean intraoperative value (T3)].
At completion of surgery inhalational anaesthetic was dis-
continued, residual neuromuscular block was antagonized
with atropine 0.02 mg/kg and neostigmine 0.08 mg/kg.
After extubation, patients were transferred to the surgical
intensive care unit (SICU). All patients received oxygen via na-
sal catheter at FIO2 0.4. Each patient was reminded of how to
operate the PCEA device after receiving an initial dose of 5 ml
of PCEA solution containing bupivacaine 0.125% and fenta-
nyl 2 lg/ml at the ﬁrst trigger. The subsequent PCEA was
set to deliver a bolus dose of 5 ml with lock-out of 15 min
and a 4 h limit of 40 ml without continuous basal infusion. If
Table 1 Demographic data of both groups [mean ± SD,
number or ratio].
Group C
n= 20
Group NG
n= 20
Age 42.3 ± 12.3 43.6 ± 9.7
Male/female 8/12 9/11
ASA (I/II) 13/7 12/8
Weight (kg) 73.4 ± 8.5 69.7 ± 9.1
Height (cm) 161.7 ± 6.7 163.4 ± 5.3
Duration of surgery (min) 151.6 ± 28.3 149.7 ± 32.4
ASA= American Society of Anaesthesiologists.
Group C = control group; group NG= nitroglycerine group.
Figure 1 Perioperative mean arterial blood pressure (MAP)
values of both groups. Values are means and error bares represent
standard deviation. C = control group; NG= nitroglycerine
group. T0: before epidural anaesthesia (base line); T1: before
induction of general anaesthesia; T2: immediately after induction;
T3: mean intraoperative value; T4–T9: 1, 2, 4, 8, 12 and 24 h
postoperatively. *p< 0.05 compared to baseline. p< 0.05 com-
pared to the other group.
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was given. The time interval from PACU admission to ﬁrst
PCEA trigger, total bupivacaine and fentanyl consumption
in the ﬁrst postoperative 24 h were recorded for all patients.
Sedation score, VAS pain score, MAP and HR were re-
corded at 1, 2, 4, 8, 12 and 24 h postoperatively. Sedation
was assessed using ﬁve point scoring system: 0 = aware,
1 = drowsy, 2 = asleep/easily respond to verbal command,
3 = asleep/difﬁcult response to verbal command, 4 = asleep/
no responses to verbal command [11].
The degree of motor blockade was assessed using modiﬁed
Bromage scale (I = free movement of legs and feet, II = just
able to ﬂex the knee with free movement of the feet, III = un-
able to ﬂex the knee but with free movement of the feet,
IV = unable to move legs or feet) [12].
Incidence of postoperative side-effects [e.g. nausea and
vomiting, respiratory depression (deﬁned as RR < 10 breath/
min), hypotension, pruritis, constipation, urinary retention,
dizziness and drowsiness, Bromage score > 0] were recorded
and managed as necessary. Ondansetron 0.1 mg/kg i.v. was gi-
ven as an anti-emetic if required in the postoperative period.
At 24 h postoperative, patient satisfaction with their postop-
erative analgesia was assessed using a 101-point verbal rating
scale (VRS), with 0 = highly dissatisﬁed to 100 = completely
satisﬁed.
2.1. Statistical analysis
Assuming that a difference of 20% or more in postoperative
fentanyl consumption would be of clinical interest, a sample
size of 20 patients/group was calculated to achieve a power
of 80% and a signiﬁcance level of 0.05.
Statistical analysis was performed using SPSSwin statistical
package version 15 (SPSS Inc., Chicago, IL). Data was pre-
sented as mean (SD), median (range) or number (%) as appro-
priate. Comparison between the two groups was performed
using unpaired Student’s t-test. Sedation scores were compared
between the two group using Mann–Whitney test. Intragroup
comparison relative to baseline was performed using repeated
measure analysis (ANOVA) with post hoc Dunnet’s test if
ANOVA results were signiﬁcant. Categorical variables were
compared using Chi-square test (Fisher’s exact test) as appro-
priate. A p value <0.05 was considered signiﬁcant.
3. Results
Fifty-two patients were assessed for study eligibility, ﬁve pa-
tients failed to meet the inclusion criteria and seven were ex-
cluded due to study violations. The remaining 40 patients
were able to complete the entire study and their data were in-
cluded in the ﬁnal analysis. Both groups were comparable with
respect to age, sex, ASA physical status, and duration of sur-
gery (Table 1).
Intraoperative MAP and HR showed signiﬁcant reduction
at T2 and T3 compared to baseline in both groups with no
intergroup difference. Postoperatively, MAP and HR were sig-
niﬁcantly higher at T5 in the group C and at T6 in group NG
compared to baseline and to the other group (p< 0.05) (Figs. 1
and 2).
Time from SICU admission to ﬁrst analgesic demand
(PCEA) were signiﬁcantly longer in group NG than the group
C (p< 0.01). Total bupivacaine and fentanyl consumed in theﬁrst postoperative 24 h were signiﬁcantly less in group NG
compared to group C (p< 0.01) (Table 2).
In the control group VAS pain scores were signiﬁcantly
higher at 2 h postoperatively compared to the nitroglycerine
group while at 4 h a signiﬁcantly higher score was observed
in group NG than in the group C (p< 0.05). Subsequently,
both groups showed comparable pain scores till the end of
the study period (Fig. 3). Sedation scores were comparable
in both groups at all time intervals (Table 3).
Incidence of postoperative nausea, vomiting, pruritis and
usage of anti-emetic treatment were less frequent in group
NG than in group C but the difference was statistically insig-
niﬁcant (p> 0.05). Two patients in group NG experienced
transient motor block (Bromage score > 0) compared to four
patients in group C (p> 0.05) (Table 4).
Postoperative oxygenation was satisfactory in all patients
during the study period (none of the patients had respiratory
depression in both groups).
Patient satisfaction with their postoperative pain manage-
ment was signiﬁcantly greater in group NG than in group C
(p< 0.01) (Table 2).
Figure 2 Perioperative heart rate (HR) values of both groups.
Values are means and error bares represent standard deviation.
C = control group; NG= nitroglycerine group. T0: before epidu-
ral anaesthesia (base line); T1: before induction of general anaes-
thesia; T2: immediately after induction; T3: mean intraoperative
value; T4–T9: 1, 2, 4, 8, 12 and 24 h postoperatively. *p< 0.05
compared to baseline. p< 0.05 compared to the other group.
Table 2 Postoperative data of both groups [mean ± SD].
Group C
n= 20
Group NG
n= 20
p value
Time to 1st analgesic
dose (min)
126.75 ± 35.1 238.62 ± 54.3* <0.001
Total bupivacaine
consumption in 24 h
(mg)
118.68 ± 29.4 74.91 ± 26.34* <0.001
Total fentanyl
consumption in 24 h (lg)
194.21 ± 45.31 121.83 ± 32.5* <0.001
Patient satisfaction VRS 85.5 ± 7.6 91.3 ± 5.6* 0.009
Group C = control group; group NG= nitroglycerine group.
* p< 0.01 compared with control group.
Figure 3 Postoperative visual analogue scale in both groups.
Values are means and error bars represent standard deviation.
C = control group; NG= nitroglycerine group. *p< 0.05 com-
pared to the other group.
Table 3 Sedation score of both groups [median (range)].
Group C
n= 20
Group NG
n= 20
1 h 2 (1–2) 2 (0–2)
2 h 2 (1–2) 1 (0–2)
4 h 2 (1–2) 2 (0–2)
8 h 1 (0–2) 1 (0–2)
12 h 1 (0–2) 0 (0–1)
24 h 1 (0–2) 0 (0–1)
Group C = control group; group NG= nitroglycerine group.
Table 4 Incidence of postoperative complications of both
groups [number (%)].
Group C
n= 20
Group NG
n= 20
Nausea 6 (30%) 3 (15%)
Vomiting 3 (15%) 1 (5%)
Pruritis 4 (20%) 1 (5%)
No. of patients required anti-emetic 5 (25%) 2 (10%)
Bromage score
I 16 (80%) 18 (90%)
II 3 (15%) 2 (10%)
III 1 (5%) 0
Group C = control group; group NG= nitroglycerine group.
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The current study shows that, pre-emptive usage of 5 mg trans-
dermal nitroglycerine patch (NO donor) in patient undergoing
lower abdominal surgery using combined general epidural
anesthesia (CGEA) resulted in signiﬁcant prolongation of
postoperative analgesia, decreased postoperative analgesic
consumption and reduced postoperative related side effect
than the control group.
The aim of combining different analgesic drugs and tech-
niques is to obtain synergistic or additive action which allows
the use of a smaller dose of each agent, hence improving the
safety proﬁle and reducing related side effects [13].
As regarding the intraoperative analgesia, no signiﬁcant
changes occurred on adding nitroglycerine. This was evidenced
by insigniﬁcant differences in intraoperative hemodynamics
which could be explained by adequacy of analgesia provided
by other modalities of analgesics used in both groups.
Transdermal nitroglycerine patch application as adjuvant
to PCEA in the present work enhanced postoperative analge-
sia for 24 h after surgery. It was evidenced by delayed ﬁrst
analgesic rescue and signiﬁcantly less PCEA bupivacaine/fen-
tanyl consumption in nitroglycerine group vs. the control
group.
The time recorded to ﬁrst analgesic trigger was signiﬁcantly
shorter in the (group C) than in the (group NG)
[126.75 ± 35.1 vs. 238.62 ± 54.3 min, respectively]. This coin-
cided with the postoperative changes in hemodynamics and
VAS scores. This may be due to fading effect of epidural anal-
gesia by that time in (group C) and the synergistic effect of
nitroglycerine patch in (group NG).
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groups at 6 h postoperatively and till the end of the study per-
iod could be attributed to the usage of PCEA. However, pa-
tients in the (group NG) required a signiﬁcant less amount
of bupivacaine/fentanyl to achieve this analgesic effect than
(group C).
These ﬁndings are in accordance with Yamangushi and
Naito [14] who stated that NO interacts synergistically with
morphine after intravenous or spinal administration. Other
studies of acute postoperative pain reported that transdermal
nitroglycerine patch prolonged postoperative analgesia when
combined with intrathecal sufentanil or neostigmine [5,10].
Previous researches also showed that daily application of
5 mg transdermal nitroglycerine patch enhanced the analgesic
effect of oral morphine analgesia in chronic cancer pain with-
out increasing the frequency of adverse effects [7,15]. Lauretti
et al. [9] stated that the association of 5 mg transdermal nitro-
glycerine patch prolonged the analgesic action of 0.1 mg/kg
epidural S(+)-ketamine). In another study, Garg et al. [16]
demonstrated an increase in total effective analgesia in patients
undergoing gynaecological surgery using intrathecal bupiva-
caine and fentanyl with transdermal nitroglycerine.
The mechanism by which NO enhances analgesia is not
clear. NO is a molecule with different effects; although it is
essential in nociception, it is also an important messenger in to-
nic cholinergic pain inhibition [17]. NO-cyclic guanosine
monophosphate (cGMP) cascade is involved in acetylcholine-
or morphine-induced peripheral antinociception [3].
The activation of descending pain pathway has been shown
to involve the participation of NO through a mechanism of ac-
tion that is likely to include activation of second messengers
such as cGMP [18]. Wide-dynamic-range neurons in the super-
ﬁcial dorsal horn and high-threshold cells in the superﬁcial or
deep layers show reduced response after exposure to (cGMP)
[17].
Intrathecal or epidural fentanyl acts mainly on neurons
with opioid receptors in lamia III of the dorsal horn as well
as in lamina V and VII, producing a segmental antinociceptive
effect [19]. Neurons containing nitric oxide synthase have been
found in lamina I–III of the dorsal horn [20].
Other investigators have described the activation of adeno-
sine triphosphate (ATP) sensitive potassium channels by NO
resulting in peripheral antinociception [21].
Another possible mechanism is NO peripheral effect. Its
vasodilator action on the venous system decreases the vaso-
constrictor tone induced by the inﬂammatory process and fur-
ther reduces the oedema formation [6]. NO generators also
induce anti-inﬂammatory effects and analgesia by blocking
hyperalgesia and neurogenic components of inﬂammatory oe-
dema [22].
Basic research demonstrated that nitroglycerine activated
varied sets of brain nuclei following systemic administration
via the intervention of selected neurotransmitters and neurom-
ediators. This could support the possibility that nitroglycerine
may act as non-opioid analgesic [23].
The lower incidence of postoperative nausea, vomiting and
itching in (group NG) compared to the (group C) recorded in
the present work could be explained by signiﬁcantly lower
postoperative fentanyl consumption in the nitroglycerine
group than in control group.
In conclusion, pre-emptive usage of transdermal nitroglyc-
erine 5 mg (NO generator) 2 h before surgery as adjuvant toCGEA as a part of multimodal analgesia in lower abdominal
surgery provided signiﬁcant prolongation of postoperative
analgesia, reduction of postoperative bupivacaine and fentanyl
requirements with reduced related side effects and high pa-
tients satisfaction.
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